Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial

[1]  S. Saha.  Death and invasive mechanical ventilation risk in hospitalized COVID-19 patients treated with anti-SARS-CoV-2 monoclonal antibodies and/or antiviral agents: A systematic review and network meta-analysis protocol , 2022, PloS one.

[2]  L. Pagano,et al.  B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA) , 2022, Frontiers in Oncology.

[3]  V. Beneš,et al.  Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients , 2022, American Journal of Transplantation.

[4]  S. Sarin,et al.  Efficacy of convalescent plasma therapy in the patient with COVID-19: a randomised control trial (COPLA-II trial) , 2022, BMJ Open.

[5]  A. Casadevall,et al.  Early Outpatient Treatment for Covid-19 with Convalescent Plasma , 2022, The New England journal of medicine.

[6]  R. Hájek,et al.  Successful early use of anti‐SARS‐CoV‐2 monoclonal neutralizing antibodies in SARS‐CoV‐2 infected hematological patients – A Czech multicenter experience , 2022, Hematological oncology.

[7]  D. Fremont,et al.  An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies , 2022, Nature Medicine.

[8]  E. Lanoy,et al.  Convalescent plasma improves overall survival in patients with B-cell lymphoid malignancy and COVID-19: a longitudinal cohort and propensity score analysis , 2022, Leukemia.

[9]  D. Esposito,et al.  mRNA vaccine-induced antibodies more effective than natural immunity in neutralizing SARS-CoV-2 and its high affinity variants , 2021, Scientific Reports.

[10]  C. S. Kow,et al.  The use of neutralizing monoclonal antibodies and risk of hospital admission and mortality in patients with COVID-19: a systematic review and meta-analysis of randomized trials , 2021, Immunopharmacology and immunotoxicology.

[11]  A. Barać,et al.  COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA) , 2021, Journal of Hematology & Oncology.

[12]  Y. Kreiss,et al.  Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months , 2021, The New England journal of medicine.

[13]  Peter J. Richardson,et al.  Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial. , 2021, JAMA.

[14]  Kelly A. Fusco,et al.  Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial , 2021, Nature Medicine.

[15]  M. Mohty,et al.  Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies , 2021, Blood Cancer Journal.

[16]  L. Maier-Hein,et al.  Can we predict the severe course of COVID-19 - a systematic review and meta-analysis of indicators of clinical outcome? , 2021, PloS one.

[17]  G. Matarese,et al.  Effect of time and titer in convalescent plasma therapy for COVID-19 , 2021, iScience.

[18]  E. Robilotti,et al.  Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19 , 2021, JAMA oncology.

[19]  L. Purcell,et al.  Tackling COVID-19 with neutralizing monoclonal antibodies , 2021, Cell.

[20]  R. Lilford,et al.  Is convalescent plasma futile in COVID-19? A Bayesian re-analysis of the RECOVERY randomized controlled trial , 2021, medRxiv.

[21]  Julie M. Woessner,et al.  COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study , 2021, The Lancet Rheumatology.

[22]  J. Justman,et al.  A randomized, double-blind, controlled trial of convalescent plasma in adults with severe COVID-19 , 2021, medRxiv.

[23]  M. Landray,et al.  Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial , 2021, medRxiv.

[24]  I. Douglas,et al.  Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia , 2021, The New England journal of medicine.

[25]  James Thomas,et al.  Living Systematic Review , 2021 .

[26]  F. Polack,et al.  Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults , 2021, The New England journal of medicine.

[27]  H. Rammensee,et al.  Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer , 2021 .

[28]  Smita Y. Patel,et al.  COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience , 2020, Journal of Allergy and Clinical Immunology.

[29]  D. Follmann,et al.  A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia , 2020, The New England journal of medicine.

[30]  E. Akalin,et al.  Covid-19 and Solid Organ Transplantation: A Review Article. , 2020, Transplantation.

[31]  W. Wood,et al.  Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients , 2020, Blood.

[32]  Á. Avezum,et al.  Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19 , 2020, The New England journal of medicine.

[33]  E. Wood,et al.  Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. , 2020, The Cochrane database of systematic reviews.

[34]  Andrew T. Levin,et al.  Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications , 2020, European Journal of Epidemiology.

[35]  E. Robilotti,et al.  Determinants of COVID-19 disease severity in patients with cancer , 2020, Nature Medicine.

[36]  L. Ren,et al.  Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. , 2020, JAMA.

[37]  Reem A Mustafa,et al.  Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[38]  Yuan Wei,et al.  A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 , 2020, The New England journal of medicine.

[39]  Recovery Collaborative Group.  Lopinavir-Ritonavir in Hospitalised Patients with COVID-19: Preliminary Report from a Randomised, Controlled, Open-Label, Platform Trial , 2020, SSRN Electronic Journal.

[40]  M. Okano,et al.  Cohort Study , 2020, Definitions.

[41]  K. Jaaback.  A Systematic Review and Meta-Analysis of Randomized Trials , 2007 .

[42]  David Gladstone.  Review article , 2005, Health Care Analysis.

[43]  David A. Beety.  The United Kingdom Experience , 1977, Air and Space Law.

[44]  E. Glaser.  The randomized clinical trial. , 1972, The New England journal of medicine.